

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

08 Jun 2026

### Comparison of the Efficacy of the Single Dose Azithromycin and in Combination with Moxifloxacin Based on the Syndromic and Etiologic Diagnostic Methods on Chlamydial Cervicitis

#### Protocol summary

##### Study aim

Determination and comparison of the efficacy of the single dose Azithromycin and in combination with Moxifloxacin Based on the syndromic and etiologic diagnostic methods on chlamydial cervicitis

##### Design

Clinical trial with control group; individual based; with parallel groups, one blind, randomized, phase 3 of the trial

##### Settings and conduct

18-35 years old women referring to Booali clinic in Amol with cervicitis complaints if they have inclusion criteria, after encoding with random assignment by Random application software are divided into 4 experimental groups and depending on their allocation to each group, they are diagnosed and treated. At 1 and 3 months after the start of treatment, the samples are referred for follow up. Finally, in 120 samples (30 samples per group), according to the appropriate statistical tests, the results of the comparison of each of the four groups and the results of the diagnostic value of both diagnostic methods, efficacy and side effects of the two drugs are studied.

##### Participants/Inclusion and exclusion criteria

Women aged 18-35; Having just one partner in the last two months; Not intake of drugs that interfere with Azithromycin or Moxifloxacin; Not Pregnancy; Not lactation; Absence of abnormal uterine bleeding

##### Intervention groups

Control group: Oral Azithromycin and syndromic diagnostic method Intervention group 1: Combination therapy of oral Azithromycin and oral Moxifloxacin and syndromic diagnostic method Intervention group 2: Combination therapy of oral Azithromycin and oral Moxifloxacin and etiologic diagnostic method; Real-Time PCR Intervention group 3: Oral Azithromycin and etiologic diagnostic method; Real-Time PCR

#### Main outcome variables

Status of patient's complaints; Status of clinical findings; lab results

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20100130003226N16**

Registration date: **2019-01-16, 1397/10/26**

Registration timing: **registered\_while\_recruiting**

Last update: **2019-01-16, 1397/10/26**

Update count: **0**

##### Registration date

2019-01-16, 1397/10/26

##### Registrant information

##### Name

Mahrokh Dolatian

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8820 2512

##### Email address

m\_dolatian@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-11-22, 1397/09/01

##### Expected recruitment end date

2019-05-22, 1398/03/01

##### Actual recruitment start date

empty  
**Actual recruitment end date**  
empty  
**Trial completion date**  
empty

#### **Scientific title**

Comparison of the Efficacy of the Single Dose Azithromycin and in Combination with Moxifloxacin Based on the Syndromic and Etiologic Diagnostic Methods on Chlamydial Cervicitis

#### **Public title**

Comparison of the Efficacy of the Azithromycin and in Combination with Moxifloxacin on Chlamydial Cervicitis

#### **Purpose**

Treatment

#### **Inclusion/Exclusion criteria**

##### **Inclusion criteria:**

Women aged 18-35 Having just one partner in the last two months Married and sexually active Clinical diagnosis of chlamydial cervicitis and confirmation of diagnosis by Real-Time PCR (in the etiological diagnostic group of PCR) Syndrome diagnosis of chlamydial cervicitis includes diagnosis based on a set of symptoms that can be found during the history and examination of the patient (in the diagnostic syndromic group)

##### **Exclusion criteria:**

Concomitant use of drugs that interfere with azithromycin or moxifloxacin Having a history of allergy to Quinolones or Macrolides Use of intrauterine device pregnancy and pregnancy intent in the next 3 months lactation participating in other studies and drug use over the past 4 weeks abnormal uterine bleeding

#### **Age**

From **18 years** old to **35 years** old

#### **Gender**

Female

#### **Phase**

3

#### **Groups that have been masked**

- Participant

#### **Sample size**

Target sample size: **120**

#### **Randomization (investigator's opinion)**

Randomized

#### **Randomization description**

Randomization method: Simple randomization Random unit: Individual Randomization Tool: Statistical software

#### **Blinding (investigator's opinion)**

Single blinded

#### **Blinding description**

The participants do not know in which group are assigned. The drug is delivered to the participants in sealed envelopes

#### **Placebo**

Not used

#### **Assignment**

Parallel

#### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### **1**

#### **Ethics committee**

##### **Name of ethics committee**

Ethics committee of Shahid Beheshti University of Medical Sciences

##### **Street address**

University Building No. 2, Sixth Floor, Parvaneh Str., Yemeh Ave, Shahid Chamran Highway

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1985717443

#### **Approval date**

2018-07-29, 1397/05/07

#### **Ethics committee reference number**

IR.SBMU. RETECH. REC. 1397. 309

## **Health conditions studied**

### **1**

#### **Description of health condition studied**

Chlamydial Cervicitis

#### **ICD-10 code**

A56.2

#### **ICD-10 code description**

Chlamydial infection of genitourinary tract, unspecified

## **Primary outcomes**

### **1**

#### **Description**

status of patient's complaints includes vaginal discharge, abdominal pain, painful intercourse

#### **Timepoint**

One month and three month after treatment

#### **Method of measurement**

Complaint checklist

### **2**

#### **Description**

Status of clinical findings includes swollen and fragile cervix, and mucopurulent secretions

#### **Timepoint**

One month and three month after treatment

#### **Method of measurement**

Clinical findings check list

### **3**

#### **Description**

lab results

#### **Timepoint**

One month and three month after treatment

#### **Method of measurement**

Nucleic Acid Amplification Test (Polymerase Chain Reaction)

### **Secondary outcomes**

empty

### **Intervention groups**

#### **1**

##### **Description**

Control group: Oral Azithromycin and syndromic diagnostic method. Azithromycin 1 g oral single dose (two 500mg) . Azithromycin can be taken with food, after or before meals. This is Dr Abeidi's Pharmaceutical Drug Company (IRC: 2366570648796929 / GTIN: 06260154636041). Syndromic diagnosis: Detection based on a set of symptoms found during a patient's history and examination

##### **Category**

Treatment - Drugs

#### **2**

##### **Description**

Intervention group: Combination therapy of oral azithromycin and oral moxifloxacin and syndromic diagnostic method. Azithromycin 1 g oral single dose (two 500mg). Moxifloxacin tablets 400 mg daily for 7 days. This pill is manufactured by Drug Paksh factories (IRC: 2493594828199352 / GTIN: 06260132430517). On the first day of treatment, oral azithromycin 1000 mg is administered as a single dose. Then the treatment is continued from day two to eight with oral moxifloxacin 400 mg once daily for 7 days. Syndromic diagnosis: Detection based on a set of symptoms found during a patient's history and examination

##### **Category**

Treatment - Drugs

#### **3**

##### **Description**

Intervention group: Combination therapy of oral azithromycin and oral moxifloxacin and ethiologic diagnostic method; Real-Time PCR. Azithromycin 1 g oral single dose (two 500mg) and Moxifloxacin tablets 400 mg daily for 7 days. On the first day of treatment, oral azithromycin 1000 mg is administered as a single dose. Then the treatment is continued from day two to eight with oral moxifloxacin 400 mg once daily for 7 days. Ethologic Diagnostic Method Real-Time PCR : A liquid-based sample is used for NAAT to study chlamydia.

##### **Category**

Treatment - Drugs

#### **4**

##### **Description**

Intervention group: Oral Azithromycin and ethiologic diagnostic method; Real-Time PCR. Azithromycin 1 g oral single dose (two 500mg). Ethologic Diagnostic Method Real-Time PCR : A liquid-based sample is used for NAAT to study chlamydia.

##### **Category**

Treatment - Drugs

### **Recruitment centers**

#### **1**

##### **Recruitment center**

###### **Name of recruitment center**

Booali clinic

###### **Full name of responsible person**

Doctor Masood Kamyab

###### **Street address**

No 1., Taleb amoli Ave., Booali clinic

###### **City**

Amol

###### **Province**

Mazandaran

###### **Postal code**

4616979457

###### **Phone**

+98 11 4428 4260

###### **Email**

kamyabmasood@yahoo.com

### **Sponsors / Funding sources**

#### **1**

##### **Sponsor**

###### **Name of organization / entity**

Shahid Beheshti University of Medical Sciences

###### **Full name of responsible person**

Dr. Afshin Zarghi

###### **Street address**

Iran-tehran-University Building No. 2 of ShahidBeheshti University of Medical Sciences, Parvaneh Str., Yemeni Ave, Shahid Chamran Highway

###### **City**

Tehran

###### **Province**

Tehran

###### **Postal code**

1985717443

###### **Phone**

+98 21 23871

###### **Fax**

###### **Email**

zarghi@sbmu.ac.ir

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**  
Shahid Beheshti University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

Tehran  
**Province**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 218865536671  
**Fax**  
+98 21 8820 2521  
**Email**  
sbnmf@sbmu.ac.ir

## Person responsible for general inquiries

**Contact**  
**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Mahrokh Dolatian  
**Position**  
Vice-Chancellor of Research, Faculty of Nursing and Midwifery  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Midwifery  
**Street address**  
Valiasr Str., intersection of Niyayesh  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 218865536671  
**Fax**  
+98 21 8820 2521  
**Email**  
sbnmf@sbmu.ac.ir

## Person responsible for scientific inquiries

**Contact**  
**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Mahrokh Dolatian  
**Position**  
Vice-Chancellor of Research, Faculty of Nursing and Midwifery  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Midwifery  
**Street address**  
Valiasr Str., intersection of Niyayesh  
**City**

## Person responsible for updating data

**Contact**  
**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Farnaz Mohammadzadeh  
**Position**  
Student  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Midwifery  
**Street address**  
No. 28, Aftab 38 Ave., Imam khomainsi Str.,  
**City**  
Amol  
**Province**  
Mazandaran  
**Postal code**  
4616818591  
**Phone**  
+98 11 4424 0370  
**Email**  
farnaz.mohammadzade@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**  
Undecided - It is not yet known if there will be a plan to make this available  
**Study Protocol**  
Undecided - It is not yet known if there will be a plan to make this available  
**Statistical Analysis Plan**  
Undecided - It is not yet known if there will be a plan to make this available  
**Informed Consent Form**  
Undecided - It is not yet known if there will be a plan to make this available  
**Clinical Study Report**  
Undecided - It is not yet known if there will be a plan to make this available  
**Analytic Code**  
Undecided - It is not yet known if there will be a plan to make this available  
**Data Dictionary**  
Undecided - It is not yet known if there will be a plan to make this available